View in EDS

168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC).

Saved in:
Bibliographic Details
Title: 168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC).
Authors: Halmos, B.1 (AUTHOR), Cobb, P.2 (AUTHOR), Johnson, M.L.3 (AUTHOR), Jain, L.4 (AUTHOR), Kim, S.J.4 (AUTHOR), Saraf, S.4 (AUTHOR), Lala, M.4 (AUTHOR), Kurata, T.5 (AUTHOR)
Source: Annals of Oncology. 2021 Supplement 7, Vol. 32, pS1456-S1456. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2021.10.187